Real-World Outcomes of Oral VEGFR Tyrosine Kinase Inhibitor-Containing Therapy in Unresectable Malignant Mesothelioma: A Single-Center Retrospective Study
- 1State Key Laboratory of Molecular Oncology, Beijing Key Laboratory, CAMS Key Laboratory of Translational Research on Lung Cancer, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Abstract
Background: Systemic treatment choices after failure of standard therapy are limited for malignant mesothelioma. Oral vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) have been incorporated into salvage treatment strategies, but real-world evidence regarding their effectiveness and safety remains scarce. Methods: We retrospectively analyzed a single-center cohort comprising patients with pathologically confirmed malignant mesothelioma treated at Cancer Hospital, Chinese Academy of Medical Sciences/National Cancer Center between 1 April 2017 and 16 March 2023. Patients with unresectable disease who received a VEGFR-TKI-containing regimen and had sufficient clinical follow-up for outcome assessment were included. Progression-free survival (PFS) served as the primary endpoint. Objective response rate (ORR), disease control rate (DCR), overall survival (OS) from VEGFR-TKI initiation, and recorded adverse events were included as secondary endpoints. Results: The cohort comprised 48 patients, with a median follow-up of 24.0 months. The Kaplan–Meier estimated median PFS was 4.8 months (95% CI, 2.9–8.8), and median OS from VEGFR-TKI initiation was 17.9 months (95% CI, 13.5–not estimable). Among 39 response-evaluable patients, 6 achieved partial response, 20 had stable disease, and 13 had progressive disease as their best overall response, yielding an ORR of 15.4% and a DCR of 66.7%. Two patients remained progression-free for more than 24 months. Grade 3 adverse events in the records included hematuria, hypertension, and nausea/vomiting; no grade 4 or grade 5 adverse event was documented. Conclusions: VEGFR-TKI-containing therapy was associated with clinically relevant disease control in unresectable malignant mesothelioma, with durable benefit observed in a small subset of patients. These observations warrant further evaluation of VEGFR-TKI-based salvage strategies in larger multicenter cohorts.
Related
- Epidemiology, exposure patterns and survival of malignant mesothelioma in Apulia, Italy (1993–2025): a population-based retrospective registry study
- Machine learning, molecular docking, and experimental validation identify shared molecular signatures between idiopathic pulmonary arterial hypertension and malignant pleural mesothelioma: a retrospective study.
- Desmoplastic Malignant Mesothelioma of the Pericardium Mimicking Inflammatory Pericardial Disease: An Autopsy Case Report
- Hexokinase II as a Potential Target of Apigenin Through the Induction of Apoptosis and Necroptosis in Malignant Mesothelioma
- Feasibility and Safety of a Novel Pig‐tail Inside Stent for Unresectable Malignant Hilar Biliary Obstruction: A Single‐center Case Series (With Video)
BibTeX
@article{liu2026realworld,
title = {{Real-World Outcomes of Oral VEGFR Tyrosine Kinase Inhibitor-Containing Therapy in Unresectable Malignant Mesothelioma: A Single-Center Retrospective Study}},
author = {Zheng Liu and Jia Zhong and Rui Wan and Jian-Chun Duan and Zhi-Jie Wang and Hua Bai and Jie Wang},
journal = {Cancers},
year = {2026},
month = nov,
doi = {10.3390/cancers18213541},
url = {https://www.mdpi.com/2072-6694/18/21/3541},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Real-World Outcomes of Oral VEGFR Tyrosine Kinase Inhibitor-Containing Therapy in Unresectable Malignant Mesothelioma: A Single-Center Retrospective Study
AU - Zheng Liu
AU - Jia Zhong
AU - Rui Wan
AU - Jian-Chun Duan
AU - Zhi-Jie Wang
AU - Hua Bai
AU - Jie Wang
PY - 2026
DA - 2026/11/04
JO - Cancers
DO - 10.3390/cancers18213541
UR - https://www.mdpi.com/2072-6694/18/21/3541
AB - Background: Systemic treatment choices after failure of standard therapy are limited for malignant mesothelioma. Oral vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) have been incorporated into salvage treatment strategies, but real-world evidence regarding their effectiveness and safety remains scarce. Methods: We retrospectively analyzed a single-center cohort comprising patients with pathologically confirmed malignant mesothelioma treated at Cancer Hospital, Chinese Academy of Medical Sciences/National Cancer Center between 1 April 2017 and 16 March 2023. Patients with unresectable disease who received a VEGFR-TKI-containing regimen and had sufficient clinical follow-up for outcome assessment were included. Progression-free survival (PFS) served as the primary endpoint. Objective response rate (ORR), disease control rate (DCR), overall survival (OS) from VEGFR-TKI initiation, and recorded adverse events were included as secondary endpoints. Results: The cohort comprised 48 patients, with a median follow-up of 24.0 months. The Kaplan–Meier estimated median PFS was 4.8 months (95% CI, 2.9–8.8), and median OS from VEGFR-TKI initiation was 17.9 months (95% CI, 13.5–not estimable). Among 39 response-evaluable patients, 6 achieved partial response, 20 had stable disease, and 13 had progressive disease as their best overall response, yielding an ORR of 15.4% and a DCR of 66.7%. Two patients remained progression-free for more than 24 months. Grade 3 adverse events in the records included hematuria, hypertension, and nausea/vomiting; no grade 4 or grade 5 adverse event was documented. Conclusions: VEGFR-TKI-containing therapy was associated with clinically relevant disease control in unresectable malignant mesothelioma, with durable benefit observed in a small subset of patients. These observations warrant further evaluation of VEGFR-TKI-based salvage strategies in larger multicenter cohorts.
SN - 2072-6694
ER -